FDA Reviews Natalizumab For Sandoz And Polpharma

Firms Follow First EU Submission With BLA Acceptance In The US

 
• By Dave Wallace

Sandoz and Polpharma have quickly followed news of a European natalizumab filing with confirmation that the proposed biosimilar version of Tysabri has also been accepted for review by the US Food and Drug Administration.

EU US Cogs Flags
Sandoz and Polpharma now have EU and US filings in the works • Source: Shutterstock

More from Biosimilars

More from Products